| Literature DB >> 23454761 |
Dudley W Lamming1, Lan Ye, David M Sabatini, Joseph A Baur.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23454761 PMCID: PMC3582126 DOI: 10.1172/JCI64099
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808